Savant Capital LLC Grows Stock Holdings in McKesson Co. (NYSE:MCK)

Savant Capital LLC raised its position in shares of McKesson Co. (NYSE:MCK) by 34.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 18,403 shares of the company’s stock after buying an additional 4,684 shares during the period. Savant Capital LLC’s holdings in McKesson were worth $10,488,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Angeles Wealth Management LLC boosted its position in shares of McKesson by 6.3% during the fourth quarter. Angeles Wealth Management LLC now owns 472 shares of the company’s stock worth $269,000 after buying an additional 28 shares during the period. Newbridge Financial Services Group Inc. raised its stake in shares of McKesson by 8.5% in the fourth quarter. Newbridge Financial Services Group Inc. now owns 673 shares of the company’s stock valued at $383,000 after acquiring an additional 53 shares in the last quarter. Kestra Private Wealth Services LLC raised its stake in shares of McKesson by 7.5% in the fourth quarter. Kestra Private Wealth Services LLC now owns 4,578 shares of the company’s stock valued at $2,609,000 after acquiring an additional 319 shares in the last quarter. Quotient Wealth Partners LLC acquired a new stake in shares of McKesson in the fourth quarter valued at $210,000. Finally, AlphaStar Capital Management LLC acquired a new stake in shares of McKesson in the fourth quarter valued at $203,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

McKesson Stock Performance

Shares of MCK stock opened at $603.33 on Tuesday. The stock’s 50-day moving average is $588.40 and its two-hundred day moving average is $562.55. The firm has a market cap of $76.59 billion, a price-to-earnings ratio of 27.63, a PEG ratio of 1.30 and a beta of 0.52. McKesson Co. has a 1 year low of $464.42 and a 1 year high of $637.51.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. As a group, research analysts predict that McKesson Co. will post 32.69 EPS for the current year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Monday, March 3rd will be issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date is Monday, March 3rd. McKesson’s dividend payout ratio is currently 13.00%.

Insider Buying and Selling

In related news, EVP Leann B. Smith sold 579 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total transaction of $331,645.41. Following the transaction, the executive vice president now owns 864 shares of the company’s stock, valued at $494,890.56. This trade represents a 40.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.11% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MCK. Wells Fargo & Company increased their price objective on McKesson from $535.00 to $641.00 and gave the company an “equal weight” rating in a research note on Friday, December 13th. Mizuho began coverage on McKesson in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $630.00 price objective on the stock. Evercore ISI increased their price objective on McKesson from $650.00 to $675.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Baird R W upgraded McKesson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. Finally, StockNews.com upgraded McKesson from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $645.79.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.